The Conversation (0)
- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Precipio announced it received an order for the launch of their RUO ICE COLD-PCR (ICP) Liquid Biopsy technology in Singapore by Clearbridge Health.
Precipio (NASDAQ:PRPO) announced it received an order for the launch of their RUO ICE COLD-PCR (ICP) Liquid Biopsy technology in Singapore by Clearbridge Health.
As quoted in the press release:
CBH has placed an initial order of ICP kits to be delivered during Q4 of 2017 and Q1 2018. The Company also announced that CBH intends to launch Precipio’s Pathology services, as well as its SmartPath™ Second Opinion service. SmartPath™ connects the patient and their treating physician with experts within Precipio’s academic network to ensure accurate diagnoses. Precipio recently conducted comprehensive training at CBH headquarters in Singapore with the CBH sales team representatives covering Singapore, China, Hong Kong, India, Philippines, Malaysia and Indonesia.
“We are very excited about ICE COLD-PCR™ technology and Smartpath™,” said Jeremy Yee, CEO of Clearbridge Health.
Click here to read the full press release.
Source: www.accesswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.